December 22, 2025 /

Webinar: Capricor Therapeutics — HOPE-3 Community Update

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

PPMD recently held a community webinar with Capricor Therapeutics, during which the company shared their most recent results from the Phase 3 HOPE-3 trial evaluating deramiocel (CAP-1002), Capricor’s investigational cell therapy for the treatment of Duchenne muscular dystrophy. The presentation included a review of the data, a discussion of planned next steps for FDA engagement and regulatory strategy, and a dedicated Q&A period.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo